

David Z I Cherney

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9174998/david-z-i-cherney-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

174
papers

7,978
citations

44
h-index

85
g-index

201
ext. papers

10,662
ext. citations

8
avg, IF

6.58
L-index

#	Paper	IF	Citations
174	The association between physical activity time and neuropathy in longstanding type 1 diabetes: A cross-sectional analysis of the Canadian study of longevity in type 1 diabetes.. <i>Journal of Diabetes and Its Complications</i> , 2022 , 36, 108134	3.2	0
173	Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease. <i>Metabolism: Clinical and Experimental</i> , 2022 , 126, 154918	12.7	6
172	Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].. <i>Diabetologia</i> , 2022 , 65, 908	10.3	
171	Potential Use of SGLT-2 Inhibitors in Obstructive Sleep Apnea: A new treatment on the horizon.. <i>Sleep and Breathing</i> , 2022 , 1	3.1	0
170	Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.. <i>Diabetologia</i> , 2022 , 1	10.3	1
169	Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials.. <i>Circulation</i> , 2022 ,	16.7	8
168	A Unique Multi- and Interdisciplinary Cardiology-Renal-Endocrine Clinic: A Description and Assessment of Outcomes.. <i>Canadian Journal of Kidney Health and Disease</i> , 2022 , 9, 20543581221081207	2.3	0
167	SGLT2 Inhibition in Patients With Type 2 Diabetes Mellitus Post-Nephrectomy: A Single-Center Case Series.. <i>Canadian Journal of Kidney Health and Disease</i> , 2021 , 8, 20543581211065528	2.3	
166	Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors.. <i>Med</i> , 2021 , 2, 1203-1230	31.7	3
165	Case - Reflex anuria: A rare complication of retrograde pyelography. <i>Canadian Urological Association Journal</i> , 2021 , 15, E380-E382	1.2	2
164	Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. <i>Diabetologia</i> , 2021 , 64, 1256-1267	10.3	28
163	Discoveries from the study of longstanding type 1 diabetes. <i>Diabetologia</i> , 2021 , 64, 1189-1200	10.3	4
162	Cardiorenal Protection in Diabetic Kidney Disease. <i>Endocrinology and Metabolism</i> , 2021 , 36, 256-269	3.5	4
161	Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 1278-1280	6.9	16
160	Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1961-1967	6.7	3
159	Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2021 , 30, 474-481	3.5	1
158	Relationships between inflammation, hemodynamic function and RAAS in longstanding type 1 diabetes and diabetic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107880	3.2	2

157	Transforming the Care of Patients with Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 1590-1600	6.9	1
156	Kidney outcomes using a sustained 40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials. <i>Clinical Cardiology</i> , 2021 , 44, 1139-1143	3.3	6
155	Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 1345-1354	6.9	4
154	Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis. <i>International Urology and Nephrology</i> , 2021 , 1	2.3	2
153	Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. <i>JAMA Cardiology</i> , 2021 , 6, 148-158	16.2	194
152	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2021 , 384, 129-139	59.2	243
151	Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations From VERTIS CV. <i>Circulation</i> , 2021 , 143, 602-605	16.7	11
150	Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors. <i>Nephrology</i> , 2021 , 26, 377-390	2.2	4
149	Characterization and implications of the initial estimated glomerular filtration rate dip upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. <i>Kidney International</i> , 2021 , 99, 750-762	9.9	33
148	Changes in Cardiovascular Biomarkers Associated With the Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Diabetes Care</i> , 2021 , 44, e45-e47	14.6	11
147	DAPA-CKD: The Beginning of a New Era in Renal Protection. <i>JACC Basic To Translational Science</i> , 2021 , 6, 74-77	8.7	5
146	Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 517-525	6.2	0
145	Vasopressin associated with renal vascular resistance in adults with longstanding type 1 diabetes with and without diabetic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107807	3.2	3
144	Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2466-2475	6.7	2
143	Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2632-2642	6.7	2
142	Cardiometabolic and Kidney Protection in Kidney Transplant Recipients with Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials. <i>Transplantation</i> , 2021 ,	1.8	2
141	Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes. <i>Kidney International Reports</i> , 2021 , 6, 2095-2104	4.1	3
140	Kidney Effects of Empagliflozin in People with Type 1 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 1715-1719	6.9	1

139	Tubular injury in diabetic ketoacidosis: Results from the diabetic kidney alarm study. <i>Pediatric Diabetes</i> , 2021 , 22, 1031-1039	3.6	2
138	A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. <i>Kidney International</i> , 2021 ,	9.9	9
137	Allopurinol and Renal Outcomes in Adults With and Without Type 2 Diabetes: A Retrospective, Population-Based Cohort Study and Propensity Score Analysis. <i>Canadian Journal of Diabetes</i> , 2021 , 45, 641-649.e4	2.1	1
136	Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 582-593	18.1	64
135	The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 895-897	4.3	12
134	Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review. <i>Canadian Journal of Kidney Health and Disease</i> , 2020 , 7, 2054358120935701	2.3	6
133	Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 274-282	4.3	105
132	The authors reply. <i>Kidney International</i> , 2020 , 97, 213-214	9.9	
131	Effect of Uric Acid-Lowering Agents on Cardiovascular Outcome in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies. <i>Angiology</i> , 2020 , 71, 315-323	2.1	13
130	CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 159-169	3.8	50
129	Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. <i>Diabetologia</i> , 2020 , 63, 1128-1140	10.3	22
128	What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22 Suppl 1, 55-68	6.7	11
127	Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure. <i>Heart Failure Reviews</i> , 2020 , 25, 685-701	5	6
126	The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications. <i>Endocrine Reviews</i> , 2020 , 41,	27.2	29
125	Preventing CKD in Developed Countries. <i>Kidney International Reports</i> , 2020 , 5, 263-277	4.1	24
124	Tubuloglomerular Feedback in Renal Glucosuria: Mimicking Long-term SGLT-2 Inhibitor Therapy. <i>Kidney Medicine</i> , 2020 , 2, 76-79	2.8	3
123	Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus. <i>American Journal of Nephrology</i> , 2020 , 51, 74-82	4.6	11
122	The Effect of Urine pH and Urinary Uric Acid Levels on the Development of Contrast Nephropathy. <i>Kidney and Blood Pressure Research</i> , 2020 , 45, 131-141	3.1	5

121	Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. <i>Circulation</i> , 2020 , 142, 2205-2215	16.7	77
120	Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank. <i>International Journal of Obesity</i> , 2020 , 44, 2256-2266	5.5	3
119	Relative Hypoxia and Early Diabetic Kidney Disease in Type 1 Diabetes. <i>Diabetes</i> , 2020 , 69, 2700-2708	0.9	12
118	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 1700-1711	4.3	52
117	Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2020 , 383, 1425-1435	59.2	418
116	Antidiuretic Hormone and Serum Osmolarity Physiology and Related Outcomes: What Is Old, What Is New, and What Is Unknown?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 5406-5420	5.6	13
115	Biomarkers of Inflammation, Fibrosis, and Acute Kidney Injury in Patients with Heart Failure with and without Left Ventricular Assist Device Implantation. <i>CardioRenal Medicine</i> , 2019 , 9, 108-116	2.8	2
114	Estimating GFR by Serum Creatinine, Cystatin C, and β -Microglobulin in Older Adults: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Kidney International Reports</i> , 2019 , 4, 786-796	4.1	8
113	Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 1716-1723	14.6	5
112	Risk factors for diabetic kidney disease in adults with longstanding type 1 diabetes: results from the Canadian Study of Longevity in Diabetes. <i>Renal Failure</i> , 2019 , 41, 427-433	2.9	3
111	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data. <i>Diabetes Care</i> , 2019 , 42, 1454-1463	14.6	28
110	A Big Win for Diabetic Kidney Disease: CREDENCE. <i>Cell Metabolism</i> , 2019 , 29, 1024-1027	24.6	15
109	Analysis from the EMPA-REG OUTCOME trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. <i>Kidney International</i> , 2019 , 96, 489-504	9.9	47
108	Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21 Suppl 2, 24-33	6.7	9
107	Molecular regulation of the renin-angiotensin system by sodium-glucose cotransporter 2 inhibition in type 1 diabetes mellitus. <i>Diabetologia</i> , 2019 , 62, 1090-1093	10.3	13
106	Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes. <i>American Journal of Kidney Diseases</i> , 2019 , 73, 786-796	7.4	7
105	The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 1921-1929	14.6	21
104	Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2368-2383	6.7	26

103	Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging. <i>Circulation</i> , 2019 , 140, 303-315	16.7	114
102	Association between uric acid, renal haemodynamics and arterial stiffness over the natural history of type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1388-1398	6.7	8
101	Bone mineral density in patients with longstanding type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Journal of Diabetes and Its Complications</i> , 2019 , 33, 107324	3.2	12
100	The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 575-583	6.7	9
99	Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 273-280	14.6	8
98	Serum Uromodulin Predicts Less Coronary Artery Calcification and Diabetic Kidney Disease Over 12 Years in Adults With Type 1 Diabetes: The CACTI Study. <i>Diabetes Care</i> , 2019 , 42, 297-302	14.6	22
97	In Response. <i>Anesthesia and Analgesia</i> , 2018 , 126, 1792-1793	3.9	
96	Chronic Kidney Disease in Diabetes. <i>Canadian Journal of Diabetes</i> , 2018 , 42 Suppl 1, S201-S209	2.1	36
95	Adiposity Impacts Intrarenal Hemodynamic Function in Adults With Long-standing Type 1 Diabetes With and Without Diabetic Nephropathy: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Care</i> , 2018 , 41, 831-839	14.6	11
94	Novel therapies for diabetic kidney disease. <i>Kidney International Supplements</i> , 2018 , 8, 18-25	6.3	23
93	Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. <i>Kidney International</i> , 2018 , 94, 26-39	3.9	160
92	Improvements in peripheral vascular function with vitamin D treatment in deficient adolescents with type 1 diabetes. <i>Pediatric Diabetes</i> , 2018 , 19, 457-463	3.6	10
91	Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes. <i>Anesthesia and Analgesia</i> , 2018 , 126, 699-704	3.9	16
90	Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. <i>Kidney International</i> , 2018 , 93, 231-244	9.9	113
89	Plasma biomarkers improve prediction of diabetic kidney disease in adults with type 1 diabetes over a 12-year follow-up: CACTI study. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 1189-1196	4.3	12
88	Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2018 , 315, F1406-F1415	4.3	16
87	Hyperfiltration, urinary albumin excretion, and ambulatory blood pressure in adolescents with Type 1 diabetes mellitus. <i>American Journal of Physiology - Renal Physiology</i> , 2018 , 314, F667-F674	4.3	26
86	Beta cell preservation in patients with type 1 diabetes. <i>Nature Medicine</i> , 2018 , 24, 1089-1090	50.5	2

85	In Response. <i>Anesthesia and Analgesia</i> , 2018 , 127, 307-308	3.9	
84	The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. <i>Diabetologia</i> , 2018 , 61, 2098-2107	10.3	125
83	Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials. <i>Kidney International</i> , 2018 , 94, 459-462	9.9	25
82	Dulaglutide and renal protection in type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 588-590	10.3	11
81	Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes. <i>JCI Insight</i> , 2018 , 3,	9.9	25
80	Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study. <i>American Journal of Physiology - Renal Physiology</i> , 2018 , 314, F412-F422	4.3	46
79	Diabetes Care Disparities in Long-standing Type 1 Diabetes in Canada and the U.S.: A Cross-sectional Comparison. <i>Diabetes Care</i> , 2018 , 41, 88-95	14.6	16
78	Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New. <i>Canadian Journal of Diabetes</i> , 2018 , 42, 325-334	2.1	10
77	Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. <i>Diabetes Care</i> , 2018 , 41, 2560-2569	14.6	149
76	Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Care</i> , 2018 , 41, 2570-2578	14.6	27
75	Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes. <i>Diabetes Care</i> , 2018 , 41, e129-e130	14.6	20
74	Influence of sex on hyperfiltration in patients with uncomplicated type 1 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2017 , 312, F599-F606	4.3	17
73	Renal and Vascular Effects of Uric Acid Lowering in Normouricemic Patients With Uncomplicated Type 1 Diabetes. <i>Diabetes</i> , 2017 , 66, 1939-1949	0.9	20
72	Use of Canagliflozin in Kidney Transplant Recipients for the Treatment of Type 2 Diabetes: A Case Series. <i>Diabetes Care</i> , 2017 , 40, e75-e76	14.6	37
71	The relationship between urinary renin-angiotensin system markers, renal function, and blood pressure in adolescents with type 1 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2017 , 312, F335-F342	4.3	24
70	Neuropathy and presence of emotional distress and depression in longstanding diabetes: Results from the Canadian study of longevity in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 1318-1324	3.2	23
69	The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure. <i>JAMA Cardiology</i> , 2017 , 2, 939-940	16.2	104
68	Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1 α in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2017 , 40, 1073-1081	14.6	71

67	Urinary adenosine excretion in type 1 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2017 , 313, F184-F191	4.3	29
66	Calcium channel blockade blunts the renal effects of acute nitric oxide synthase inhibition in healthy humans. <i>American Journal of Physiology - Renal Physiology</i> , 2017 , 312, F870-F878	4.3	3
65	Response to Comment on Lovshin et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1 in Patients With Type 2 Diabetes. <i>Diabetes Care</i> 2017;40:1073-1081. <i>Diabetes Care</i> , 2017 , 40, e159-e160	14.6	
64	Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. <i>Circulation</i> , 2017 , 136, 1643-1658	16.7	256
63	The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome. <i>PLoS ONE</i> , 2017 , 12, e0186910	3.7	15
62	Relationship between serum inflammatory markers and vascular function in a cohort of adolescents with type 1 diabetes. <i>Cytokine</i> , 2017 , 99, 233-239	4	16
61	Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 610-621	18.1	217
60	Lower corneal nerve fibre length identifies diabetic neuropathy in older adults with diabetes: results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetologia</i> , 2017 , 60, 2529-2531	10.3	12
59	Hemodynamic and neurochemical determinates of renal function in chronic heart failure. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2016 , 310, R167-75	3.2	9
58	Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort. <i>Cardiovascular Diabetology</i> , 2016 , 15, 14	8.7	22
57	The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. <i>Diabetologia</i> , 2016 , 59, 1860-70	10.3	112
56	Early changes in cardiovascular structure and function in adolescents with type 1 diabetes. <i>Cardiovascular Diabetology</i> , 2016 , 15, 31	8.7	46
55	Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. <i>Kidney International</i> , 2016 , 89, 524-6	9.9	85
54	Association Between Plasma Uric Acid Levels and Cardiorenal Function in Adolescents With Type 1 Diabetes. <i>Diabetes Care</i> , 2016 , 39, 611-6	14.6	12
53	The urinary inflammatory profile in gluten free diet-adherent adolescents with type 1 diabetes and celiac disease. <i>Journal of Diabetes and Its Complications</i> , 2016 , 30, 295-9	3.2	6
52	New and old agents in the management of diabetic nephropathy. <i>Current Opinion in Nephrology and Hypertension</i> , 2016 , 25, 232-9	3.5	29
51	The GomezPequations and renal hemodynamic function in kidney disease research. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 311, F967-F975	4.3	26
50	Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility. <i>Circulation</i> , 2016 , 134, 1915-1917	16.7	32

49	Prevalence of Insulin Pump Therapy and Its Association with Measures of Glycemic Control: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2016 , 18, 298-307	8.1	22
48	Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. <i>Circulation</i> , 2016 , 134, 752-72	16.7	631
47	Uric acid as a biomarker and a therapeutic target in diabetes. <i>Canadian Journal of Diabetes</i> , 2015 , 39, 239-46	2.1	77
46	GLP-1R Agonists and Endothelial Dysfunction: More Than Just Glucose Lowering?. <i>Diabetes</i> , 2015 , 64, 2319-21	0.9	13
45	Reference values for pulse wave Doppler and tissue Doppler imaging in pediatric echocardiography. <i>Circulation: Cardiovascular Imaging</i> , 2015 , 8, e002167	3.9	58
44	Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. <i>Current Opinion in Nephrology and Hypertension</i> , 2015 , 24, 96-103	3.5	104
43	Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. <i>American Journal of Physiology - Renal Physiology</i> , 2015 , 308, F77-83	4.3	105
42	The effect of sex on humanin levels in healthy adults and patients with uncomplicated type 1 diabetes mellitus. <i>Canadian Journal of Physiology and Pharmacology</i> , 2015 , 93, 239-43	2.4	5
41	Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes. <i>PLoS ONE</i> , 2015 , 10, e0141085	3.7	26
40	The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2014 , 13, 28	8.7	313
39	The effect of sex on endothelial function responses to clamped hyperglycemia in type 1 diabetes. <i>Hypertension Research</i> , 2014 , 37, 220-4	4.7	1
38	Renal hyperfiltration is associated with glucose-dependent changes in fractional excretion of sodium in patients with uncomplicated type 1 diabetes. <i>Diabetes Care</i> , 2014 , 37, 2774-81	14.6	5
37	Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?. <i>Canadian Journal of Diabetes</i> , 2014 , 38, 356-63	2.1	32
36	The urinary cytokine/chemokine signature of renal hyperfiltration in adolescents with type 1 diabetes. <i>PLoS ONE</i> , 2014 , 9, e111131	3.7	16
35	Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. <i>Kidney International</i> , 2014 , 86, 1057-8	9.9	80
34	Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. <i>Diabetes Care</i> , 2014 , 37, 1480-3	14.6	186
33	Urinary ACE2 in healthy adults and patients with uncomplicated type 1 diabetes. <i>Canadian Journal of Physiology and Pharmacology</i> , 2014 , 92, 703-6	2.4	20
32	Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. <i>Diabetologia</i> , 2014 , 57, 2599-602	10.3	102

31	Early diabetic nephropathy in type 1 diabetes: new insights. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2014 , 21, 279-86	4	81
30	Gender, clamped hyperglycemia and arterial stiffness in patients with uncomplicated type 1 diabetes mellitus. <i>Clinical and Experimental Hypertension</i> , 2014 , 36, 187-93	2.2	7
29	Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. <i>Circulation</i> , 2014 , 129, 587-97	16.7	834
28	Prucalopride-associated acute tubular necrosis. <i>World Journal of Clinical Cases</i> , 2014 , 2, 380-4	1.6	5
27	Fasting blood glucose--a missing variable for GFR-estimation in type 1 diabetes?. <i>PLoS ONE</i> , 2014 , 9, e96364	3.4	11
26	The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes. <i>Diabetologia</i> , 2013 , 56, 2308-17	10.3	13
25	Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. <i>Current Diabetes Reports</i> , 2013 , 13, 550-9	5.6	120
24	Long-term hemodynamic and molecular effects persist after discontinued renin-angiotensin system blockade in patients with type 1 diabetes mellitus. <i>Kidney International</i> , 2013 , 84, 1246-53	9.9	9
23	Sex differences in renal responses to hyperglycemia, L-arginine, and L-NMMA in humans with uncomplicated type 1 diabetes. <i>Diabetes Care</i> , 2013 , 36, 1290-6	14.6	12
22	Renal hyperfiltration and systemic blood pressure in patients with uncomplicated type 1 diabetes mellitus. <i>PLoS ONE</i> , 2013 , 8, e68908	3.7	18
21	Systemic hemodynamic function in humans with type 1 diabetes treated with protein kinase C β inhibition and renin-angiotensin system blockade: a pilot study. <i>Canadian Journal of Physiology and Pharmacology</i> , 2012 , 90, 113-21	2.4	8
20	Cystatin C and acute changes in glomerular filtration rate. <i>Clinical Nephrology</i> , 2012 , 78, 64-75	2.1	38
19	Renal hyperfiltration related to diabetes mellitus and obesity in human disease. <i>World Journal of Diabetes</i> , 2012 , 3, 1-6	4.7	102
18	Hyperfiltration and effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2012 , 303, R710-8	3.2	54
17	Ability of Cystatin C to detect changes in glomerular filtration rate after ACE inhibition in patients with uncomplicated type 1 diabetes. <i>Clinical and Experimental Hypertension</i> , 2012 , 34, 606-11	2.2	6
16	The effect of direct renin inhibition alone and in combination with ACE inhibition on endothelial function, arterial stiffness, and renal function in type 1 diabetes. <i>Diabetes Care</i> , 2012 , 35, 2324-30	14.6	40
15	Evolution of renal hyperfiltration and arterial stiffness from adolescence into early adulthood in type 1 diabetes. <i>Diabetes Care</i> , 2011 , 34, 1821-6	14.6	15
14	The acute effect of clamped hyperglycemia on the urinary excretion of inflammatory cytokines/chemokines in uncomplicated type 1 diabetes: a pilot study. <i>Diabetes Care</i> , 2011 , 34, 177-80	14.6	46

13	Renal hyperfiltration is a determinant of endothelial function responses to cyclooxygenase 2 inhibition in type 1 diabetes. <i>Diabetes Care</i> , 2010 , 33, 1344-6	14.6	55
12	Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study. <i>Diabetes Care</i> , 2010 , 33, 361-5	14.6	76
11	Renal hyperfiltration and arterial stiffness in humans with uncomplicated type 1 diabetes. <i>Diabetes Care</i> , 2010 , 33, 2068-70	14.6	29
10	Age is a determinant of acute hemodynamic responses to hyperglycemia and angiotensin II in humans with uncomplicated type 1 diabetes mellitus. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2010 , 299, R206-14	3.2	24
9	The angiotensin II receptor type 2 polymorphism influences haemodynamic function and circulating RAS mediators in normotensive humans. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 4093-6	4.3	9
8	Effect of protein kinase Cbeta inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study. <i>Diabetes Care</i> , 2009 , 32, 91-3	14.6	36
7	The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. <i>Diabetes</i> , 2008 , 57, 688-95	0.9	72
6	Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus. <i>American Journal of Physiology - Renal Physiology</i> , 2008 , 294, F1336-41	4.3	37
5	Insights into the regulation of renal hemodynamic function in diabetic mellitus. <i>Current Diabetes Reviews</i> , 2008 , 4, 280-90	2.7	44
4	Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 1703-9	12.7	103
3	Gender differences in renal responses to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes. <i>Kidney International</i> , 2005 , 68, 1722-8	9.9	65
2	Natural history and outcome of incarcerated abdominal hernias in peritoneal dialysis patients. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2004 , 20, 86-9		25
1	Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature. <i>Journal of General Internal Medicine</i> , 2002 , 17, 937-45	4	106